GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » Change In Payables And Accrued Expense

Maat Pharma (XPAR:MAAT) Change In Payables And Accrued Expense : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma Change In Payables And Accrued Expense?

Maat Pharma's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was €0.00 Mil. It means Maat Pharma's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Dec. 2024 .

Maat Pharma's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €0.00 Mil. It means Maat Pharma's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Maat Pharma Change In Payables And Accrued Expense Historical Data

The historical data trend for Maat Pharma's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma Change In Payables And Accrued Expense Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial - - - - -

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Maat Pharma Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maat Pharma Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Maat Pharma's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Maat Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
XPAR:TNG XPAR:ADOC XPAR:ALSEN XPAR:ALGAE XPAR:ABNX XPAR:ALGEN XPAR:SIGHT XPAR:POXEL XPAR:OSE XPAR:ALDVI VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
4RD:Germany
Address
70 Avenue Tony Garnier, Lyon, FRA, 69007
Website
https://www.maatpharma.com
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma Headlines

No Headlines